Marco Pravetoni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7677208/publications.pdf

Version: 2024-02-01

60	1,997	186265	254184
papers	citations	28 h-index	43 g-index

62	62	62	1398
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantification of Housekeeping Transcript Levels During the Development of Bovine Preimplantation Embryos1. Biology of Reproduction, 2002, 67, 1465-1472.	2.7	182
2	Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. Genes, Brain and Behavior, 2008, 7, 523-531.	2.2	80
3	Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine, 2012, 30, 4617-4624.	3.8	77
4	Oxycodone self-administration in male and female rats. Psychopharmacology, 2017, 234, 977-987.	3.1	77
5	An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 225-232.	2.5	73
6	A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 282-291.	2.5	67
7	Absence and Rescue of Morphine Withdrawal in GIRK/Kir3 Knock-out Mice. Journal of Neuroscience, 2008, 28, 4069-4077.	3.6	62
8	Selective Effects of a Morphine Conjugate Vaccine on Heroin and Metabolite Distribution and Heroin-Induced Behaviors in Rats. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 397-406.	2.5	61
9	Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats. PLoS ONE, 2014, 9, e101807.	2.5	61
10	Expression and Localization of RGS9-2/G 5/R7BP Complex In Vivo Is Set by Dynamic Control of Its Constitutive Degradation by Cellular Cysteine Proteases. Journal of Neuroscience, 2007, 27, 14117-14127.	3.6	60
11	Reduced Antinociception of Opioids in Rats and Mice by Vaccination with Immunogens Containing Oxycodone and Hydrocodone Haptens. Journal of Medicinal Chemistry, 2013, 56, 915-923.	6.4	59
12	Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology, 2019, 158, 107662.	4.1	59
13	Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology, 2012, 83, 543-550.	4.4	57
14	GIRK Channels Modulate Opioid-Induced Motor Activity in a Cell Type- and Subunit-Dependent Manner. Journal of Neuroscience, 2015, 35, 7131-7142.	3.6	53
15	High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine, 2012, 31, 159-164.	3.8	52
16	Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. PLoS ONE, 2017, 12, e0184876.	2.5	47
17	R7BP Complexes With RGS9-2 and RGS7 in the Striatum Differentially Control Motor Learning and Locomotor Responses to Cocaine. Neuropsychopharmacology, 2010, 35, 1040-1050.	5.4	46
18	Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats. PLoS ONE, 2014, 9, e96547.	2.5	45

#	Article	IF	Citations
19	Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system. Neuropsychopharmacology, 2020, 45, 1781-1792.	5.4	44
20	Predisposition to late-onset obesity in GIRK4 knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8148-8153.	7.1	42
21	Altered neurotransmission in the mesolimbic reward system of Girk^{â^'/â^'} mice. Journal of Neurochemistry, 2010, 114, 1487-1497.	3.9	42
22	The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. Journal of Immunology, 2015, 194, 5926-5936.	0.8	40
23	Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 346-353.	2.5	40
24	Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular Pharmaceutics, 2018, 15, 4947-4962.	4.6	40
25	Countermeasures for Preventing and Treating Opioid Overdose. Clinical Pharmacology and Therapeutics, 2021, 109, 578-590.	4.7	38
26	Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine, 2013, 31, 6185-6193.	3.8	37
27	Biologics to treat substance use disorders: Current status and new directions. Human Vaccines and Immunotherapeutics, 2016, 12, 3005-3019.	3.3	37
28	Sex differences in oral oxycodone selfâ€administration and stressâ€primed reinstatement in rats. Addiction Biology, 2020, 25, e12822.	2.6	34
29	Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 469-477.	2.5	33
30	Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochemical Pharmacology, 2011, 81, 1164-1170.	4.4	30
31	Hapten-specific naÃ¯ve B cells are biomarkers of vaccine efficacy against drugs of abuse. Journal of Immunological Methods, 2014, 405, 74-86.	1.4	29
32	Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions. PLoS ONE, 2013, 8, e82557.	2.5	26
33	Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports, 2018, 8, 5508.	3.3	26
34	Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. Journal of Medicinal Chemistry, 2020, 63, 14647-14667.	6.4	25
35	Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge. Npj Vaccines, 2021, 6, 69.	6.0	19
36	Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone. ACS Applied Bio Materials, 2019, 2, 3418-3428.	4.6	18

#	Article	IF	Citations
37	Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. Human Vaccines and Immunotherapeutics, 2019, 15, 909-917.	3.3	17
38	Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology, 2019, 44, 217-218.	5.4	16
39	The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine, 2015, 33, 6332-6339.	3.8	15
40	Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation. Molecular Pharmaceutics, 2019, 16, 2364-2375.	4.6	15
41	Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. Neuropharmacology, 2021, 195, 108653.	4.1	14
42	Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders. Npj Vaccines, 2020, 5, 99.	6.0	13
43	Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacology Biochemistry and Behavior, 2012, 102, 157-162.	2.9	12
44	Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2022, 381, 129-136.	2.5	11
45	Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats. ACS Omega, 0, , .	3.5	10
46	Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 392-403.	2.5	9
47	Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning. ACS Pharmacology and Translational Science, 2021, 4, 1654-1664.	4.9	8
48	Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats. ACS Pharmacology and Translational Science, 2022, 5, 331-343.	4.9	8
49	A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs. Analytical Chemistry, 2021, 93, 16213-16221.	6.5	7
50	Potential unintended consequences of class-wide drug scheduling based on chemical structure: A cautionary tale for fentanyl-related compounds. Drug and Alcohol Dependence, 2021, 221, 108530.	3.2	5
51	Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders. Journal of Immunology, 2021, 207, 860-867.	0.8	5
52	Inhibition of Nitric Oxide Synthase Enhances Cocaine's Developmental Toxicity: Vascular and CNS Effects. Neuropsychopharmacology, 2007, 32, 940-945.	5.4	3
53	Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Human Vaccines and Immunotherapeutics, 2021, 17, 4383-4392.	3.3	3
54	Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine, 2022, 40, 3244-3252.	3.8	3

#	Article	IF	Citations
55	Vasoconstriction Caused by Cocaine is Enhanced by Sodium Salicylate: Is Inducible Nitric Oxide Synthase mRNA Related?. Neuropsychopharmacology, 2004, 29, 1294-1300.	5.4	2
56	Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. Vaccine, 2020, 38, 4704-4712.	3.8	2
57	Is the opioid use disorder epidemic impacting our immunological health?. Brain, Behavior, and Immunity, 2020, 87, 203-204.	4.1	0
58	A covalent poly(lactic acid) naloxone nanoparticle reduces fentanylâ€induced poisoning in rats. FASEB Journal, 2021, 35, .	0.5	0
59	INDâ€enabling studies of vaccines to treat heroin and oxycodone use disorders. FASEB Journal, 2021, 35, .	0.5	0
60	B Cell Mechanisms Underlying Vaccine Efficacy Against Drugs of Abuse. , 2016, , 367-393.		0